Key Highlights

  • Consensus EPS is a loss of 0.21, against a second-quarter GAAP loss of 0.30 and non-GAAP loss of 0.26.
  • Management raised 2026 revenue guidance to USD 265 million to USD 269 million from USD 263 million to 267 million.
  • Management reiterated adjusted EBITDA guidance of approximately USD 25 million, and second-quarter adjusted EBITDA was USD 6.8 million.
  • Consensus revenue of USD 68.50 million compares with revenue of USD 70,508 thousand reported for the second quarter.

OrthoPediatrics (NASDAQ:KIDS) reports third-quarter results on Tuesday, Oct. 27, after the market closes. Consensus stands at EPS of -0.21 on revenue of USD 68.50 million, and the company has a market capitalization of USD 627.16 million.

OrthoPediatrics sells orthopedic implants and bracing products for children, and it reports trauma and deformity, scoliosis and sports medicine revenue. In the second quarter, it reported revenue of USD 70,508 thousand against USD 61,082 thousand and gross profit of USD 52,366 thousand against USD 44,019 thousand.

Estimates Against Guidance and the Last Reported Quarter

The revenue estimate of USD 68.50 million is below the USD 70,508 thousand reported for the second quarter. The EPS estimate is a loss of 0.21, against a GAAP loss of 0.30 per basic and diluted share and a non-GAAP loss of 0.26, which compared with a non-GAAP loss of 0.11.

Full-year 2026 revenue guidance is USD 265 million to USD 269 million, raised from USD 263 million to USD 267 million. Management reiterated adjusted EBITDA of approximately USD 25 million for the year.

What Management Guided and What It Left Open

Management put numbers on set deployment, which was USD 2.9 million in the second quarter and approximately USD 5 million for the first half, toward a full-year target of USD 10 million.

The CFO said some 7D sales are anticipated in the second half, which would pressure gross margin because capital sales carry lower margin, and gave no margin figure. The CEO said timing of capital placements and international set sales weighed on scoliosis growth in the quarter.

Changes in the Latest Results

Revenue rose 15%. Trauma and deformity revenue was USD 52.6 million, up 26%, and scoliosis revenue was USD 16.9 million, down 9% on zero 7D Technology unit sales and fewer international set sales to stocking distributors in Brazil. Domestic revenue was USD 54.8 million and international revenue was USD 15.7 million.

Gross margin was 74% against 72%, and operating expenses were USD 56,434 thousand against USD 54,676 thousand. Operating loss was USD 4,068 thousand against USD 10,657 thousand, and net loss was USD 7,163 thousand against USD 7,113 thousand.

Sales and marketing expense was USD 21.3 million and general and administrative expense was USD 32.8 million. Free cash flow was a USD 3.1 million usage against USD 13.9 million, and cash, short-term investments and restricted cash were USD 47.9 million, with USD 20 million of term loan capacity available.

The estimates table lists a market capitalization of USD 627.16 million.

Items to Track in the Report

Revenue against USD 68.50 million and the loss per share against 0.21 are the headline comparisons. Other markers are the USD 265 million to USD 269 million revenue guide, gross margin against 74% and scoliosis revenue.